Benzinga | Sep 30, 2021 04:32PM EDT

Tango Therapeutics Announces Presentation Of Preclinical Data On Lead Program And Discovery Platform In Five Abstracts Accepted At AACR-NCI-EORTC 2021

Tango Therapeutics, Inc. (NASDAQ:TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for presentation as virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 7 -- 10, 2021.

"The preclinical data being presented today highlight the potential applicability of synthetic lethal drug targeting across a range of cancer types. As an example, our lead program, TNG908, an MTA-cooperative PRMT5 inhibitor selective for cancers with deletion of the MTAP gene, shows strong regressions across multiple types of cancer," said Barbara Weber, M.D., president and Chief Executive Officer of Tango Therapeutics. "We look forward to leveraging these data to inform our planned clinical development program."

Dr. Weber will also be co-chairing an Educational session titled "Exploiting Synthetic Lethality" on October 7, 2021 at 10:00 AM ET.

Details on Tango's presentations at AACR-NCI-EORTC are as follows:

Poster Title: MTAPnull-selective PRMT5 inhibitors drive regressions in MTAP-deleted xenograft models across histologies

Abstract #: P214

Date and Time October 7, 9:00 AM ET

Poster Title: VRK1 is a novel synthetic lethal target in VRK2-methylated glioblastoma

Abstract #: P182

Date and Time October 7, 9:00 AM ET

Poster Title: CRISPR screens identify sensitizers to Trametinib in KRAS mutant cancer cell lines

Abstract #: P183

Date and Time October 7, 9:00 AM ET

Poster Title: Loss of HS2ST1 cooperates with MAPK inhibition to impair growth of mesenchymal KRAS mutant NSCLC

Abstract #: P146

Date and Time October 7, 9:00 AM ET

Poster Title: Isogenic CRISPR Anchor Screens identified actionable nodes to CHK1/2 inhibitor Prexasertib in TP53 mutant cancer

Abstract #: P095

Date and Time October 7, 9:00 AM ET